5 months on semaglutide Two-year effects of in adults with overweight or obesity: the STEP trial Your First 3 Months on

Phase 2 readout expected BXCL502BXCL502 / latrepirdine / NeuroscienceChronic agitation in dementiaPreclinicalDevelopment paused due to strategic reprioritization BXCL503BXCL503 / NeuroscienceApathy in dementiaPreclinicalDevelopment paused due to strategic reprioritization BXCL504BXCL504 / NeuroscienceAggression in dementiaPreclinicalDevelopment paused due to strategic reprioritization BXCL702BXCL702 / DPP inhibitor / novel DPP inhibitor / Immuno-oncologySolid tumorsPreclinicalBXCL701 follow-on

If you are planning a GLP-1 program or evaluating manufacturing routes, Bachem provides integrated peptide CDMO and CMO support from process development and analytical characterization to large-scale GMP manufacturing of peptide APIs

10.1016/S0166-2236(99)01463-0

These represent far safer alternatives to unlicensed peptide combinations